Document is current
Any future updates will be listed below
-
Authors
Nghiemphu, Phioanh Leia
Ebiana, Victoria Asuquo
Wen, Patrick
Gilbert, Mark
Abrey, Lauren E.
Lieberman, F.
DeAngelis, Lisa M.
Robins, H. Ian
Yung, W. K. Alfred
Chang, Susan
Drappatz, Jan
Mehta, Minesh P.
Levin, Victor A.
Aldape, Kenneth
Dancey, Janet E.
Wright, J. J.
Prados, Michael
Kuhn, John
Cloughesy, Timothy F.
-
Funding
Funding for this research was provided by:
National Institutes of Health (U01 CA-062412)
- License Information
-
More Information
Article History
Received: 1 June 2017
Accepted: 22 September 2017
First Online: 7 October 2017
Compliance with ethical standards
:
: Dr. Chang is a consultant to Edge and Blaze and serves as research support to Route and Novartis. Dr. Dancey receives funding from AstraZeneca, Pfizer, and Merck for her institution. Dr. Wen provides research support to Agios, Angiochem, AstraZeneca, Genentech, Roche, Glaxosmith Kline, Immunocellular Therapeutics, Karyopharm, Merck, Novartis, Oncoceotics, Sanofi-Aventis. Dr. Wen serves on the advisory board for AstraZeneca, Cavion, Genentech/Roche, Insys, Monteris, Novogen, Novartis, Regeneron Vascular Biogenics, VBI Vaccines. Dr. Wen is a speaker for Merck and serves on the Data Monitoring Safety Board for Tocagen and Monteris. Dr. DeAngelis serves on the scientific advisory boards of Sapience, Roche, and Tocagen.
